GlassScriptPhysician profile
Irmak Karaca
NPI 1760101778
$128,726.96
in general payments reported to CMS, 2019-2025
13 companies · $865 in 2025
The $865 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $57K · 2023: $70K · 2024: $711 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $69K · Food and Beverage: $2,249 · Travel and Lodging: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $69,035.84 |
| Food and Beverage | $2,249.08 |
| Travel and Lodging | $224.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $126,160.15 | 2022-2024 | Eylea, Eylea Hd |
| Abbvie INC. | $395.86 | 2022-2024 | |
| Alcon Vision LLC | $376.01 | 2025 | Constellation, Unity, Finesse Sharkskin |
| Genentech USA, INC. | $334.62 | 2024-2025 | Vabysmo, Susvimo |
| Mallinckrodt Hospital Products INC. | $305.65 | 2022-2024 | Acthar |
| Biogen, INC. | $296.72 | 2023 | |
| Apellis Pharmaceuticals, INC. | $202.44 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $150.59 | 2025 | Izervay |
| Neurotech Pharmaceuticals, INC. | $139.10 | 2025 | |
| Genentech, INC. | $120.19 | 2023 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $119.84 | 2024 | Eylea Hd |
| Alimera Sciences, INC. | $92.00 | 2024 | Iluvien, Yutiq |
| Ani Pharmaceuticals, INC. | $33.79 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irmak Karaca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.